NATCO Pharma Future Growth

Future criteria checks 1/6

NATCO Pharma's earnings are forecast to decline at 8% per annum while its annual revenue is expected to grow at 2% per year. EPS is expected to decline by 8.1% per annum. Return on equity is forecast to be 21.3% in 3 years.

Key information

-8.0%

Earnings growth rate

-8.1%

EPS growth rate

Pharmaceuticals earnings growth	18.3%
Revenue growth rate	2.0%
Future return on equity	21.3%
Analyst coverage	Good
Last updated	19 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BSE:524816 - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	36,369	8,029	7,907	N/A	4
3/31/2026	55,924	20,573	16,073	N/A	11
3/31/2025	50,121	19,398	11,616	N/A	10
6/30/2024	43,490	16,365	N/A	N/A	N/A
3/31/2024	40,020	13,883	8,529	12,116	N/A
12/31/2023	38,298	12,778	N/A	N/A	N/A
9/30/2023	35,637	11,274	5,230	7,477	N/A
6/30/2023	29,630	8,152	N/A	N/A	N/A
3/31/2023	27,085	7,153	6,435	8,491	N/A
12/31/2022	24,074	3,890	N/A	N/A	N/A
9/30/2022	24,754	4,071	5,575	8,302	N/A
6/30/2022	24,191	4,154	N/A	N/A	N/A
3/31/2022	19,462	1,700	-1,962	465	N/A
12/31/2021	16,833	2,735	N/A	N/A	N/A
9/30/2021	14,780	2,558	-2,457	230	N/A
6/30/2021	18,990	3,931	N/A	N/A	N/A
3/31/2021	20,561	4,409	465	2,988	N/A
12/31/2020	21,756	4,820	N/A	N/A	N/A
9/30/2020	23,026	5,238	1,554	4,466	N/A
6/30/2020	19,861	4,404	N/A	N/A	N/A
3/31/2020	19,150	4,608	587	4,173	N/A
12/31/2019	19,159	4,875	N/A	N/A	N/A
9/30/2019	19,904	5,425	-2,200	1,600	N/A
6/30/2019	20,482	6,060	N/A	N/A	N/A
3/31/2019	20,945	6,444	2,071	6,688	N/A
12/31/2018	24,066	8,235	N/A	N/A	N/A
9/30/2018	24,121	8,815	N/A	N/A	N/A
6/30/2018	22,953	7,838	N/A	N/A	N/A
3/31/2018	21,848	6,962	N/A	4,636	N/A
12/31/2017	19,817	5,730	N/A	N/A	N/A
9/30/2017	20,895	5,506	N/A	4,985	N/A
6/30/2017	21,679	5,323	N/A	N/A	N/A
3/31/2017	20,202	4,860	N/A	3,458	N/A
12/31/2016	17,697	3,680	N/A	N/A	N/A
9/30/2016	13,692	2,113	N/A	N/A	N/A
6/30/2016	12,431	1,748	N/A	N/A	N/A
3/31/2016	10,423	1,549	N/A	1,122	N/A
12/31/2015	9,355	1,494	N/A	N/A	N/A
9/30/2015	8,549	1,266	N/A	N/A	N/A
6/30/2015	8,390	1,294	N/A	N/A	N/A
3/31/2015	7,305	1,293	N/A	927	N/A
12/31/2014	8,089	1,042	N/A	N/A	N/A
9/30/2014	8,108	1,199	N/A	N/A	N/A
6/30/2014	7,648	1,144	N/A	N/A	N/A
3/31/2014	7,389	1,027	N/A	1,440	N/A
12/31/2013	7,078	900	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 524816's earnings are forecast to decline over the next 3 years (-8% per year).

Earnings vs Market: 524816's earnings are forecast to decline over the next 3 years (-8% per year).

High Growth Earnings: 524816's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 524816's revenue (2% per year) is forecast to grow slower than the Indian market (10.2% per year).

High Growth Revenue: 524816's revenue (2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 524816's Return on Equity is forecast to be high in 3 years time (21.3%)

NATCO Pharma Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target increased by 14% to ₹1,209

Price target increased by 9.1% to ₹1,064

Price target increased by 8.9% to ₹895

Price target increased by 9.6% to ₹734

Price target decreased to ₹709

Price target decreased to ₹894

Recent updates

NATCO Pharma Limited to Report First Half, 2025 Results on Nov 12, 2024

Insider recently sold ₹30m worth of stock

High number of new directors

Natco Pharma Limited Submits Abbreviated New Drug Application Containing A Paragraph IV Certification with the U.S. Food and Drug Administration

Less than half of directors are independent

Price target increased by 14% to ₹1,209

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024

Dividend of ₹3.00 announced

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

Board Member recently sold ₹6.0m worth of stock

Investor sentiment improves as stock rises 21%

Price target increased by 9.1% to ₹1,064

Full year 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024

Now 22% undervalued

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹1.25 per share

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Insider recently bought ₹161k worth of stock

NATCO Pharma Limited Files Generic Olaparib Tablets in USA

Upcoming dividend of ₹1.25 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023

NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023

MD & Director recently bought ₹5.0m worth of stock

Natco Pharma Limited Announces Double Bench of the High Court of Delhi Dismiss an Appeal Filed by FMC Corporation, FMC Singapore and FMC India

Price target decreased to ₹709

Upcoming dividend of ₹0.75 per share

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2022-23, Payable from 30 November 2022

NATCO Pharma Limited to Report Q2, 2023 Results on Nov 10, 2022

Natco Pharma Limited Announces FMC Corporation and FMC Singapore Serve A Copy of Appeal on Natco

Natco Pharma Limited Launches Chlorantraniliprole

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2022

NATCO Announces Tentative Approval to Its ANDA for Trabectedin (Generic for Yondelis®)

Upcoming dividend of ₹3.50 per share

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on August 30, 2022

NATCO Pharma Limited to Report Q1, 2023 Results on Aug 09, 2022

NATCO Pharma Limited Announces the Launch of the First Generic Version of Nexavar® (Sorafenib) Tablets in 200 Mg Strength in the U.S. Market

Price target decreased to ₹894

Full year 2022 earnings: EPS and revenues miss analyst expectations

FMC Corporation Files a Suit against NATCO Pharma Limited

NATCO Pharma Limited to Report Q4, 2022 Results on May 30, 2022